Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The new site enables end-to-end production of viral vector gene therapies
New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization
BIL also holds an option to increase its equity stake by an additional 15%
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Subscribe To Our Newsletter & Stay Updated